Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

WERFEN

Werfen provides diagnostic instruments for critical care and hemostasis to meet the testing needs of medical professi... read more Featured Products: More products

Download Mobile App




Anticoagulant Adjustment Evaluated Using Different Prothrombin Time Tests

By LabMedica International staff writers
Posted on 26 Nov 2020
Preanalytical variables may affect the results of routine coagulation assays. More...
One important variable is hematocrit (Ht), which affects coagulation testing results. A sample with high Ht has lower plasma quantity, resulting in a dilution effect on the sample by an excess of the anticoagulant sodium citrate.

The prothrombin time/international normalized ratio (PT/INR) test is the assay used to monitor dose-adjustments of vitamin K antagonist (VKA) treatment. Thus, for patients on monitored oral anticoagulant therapy who present an elevated Ht, adjustment of sodium citrate volume is essential, otherwise, these patients would have an incorrect diagnosis or treatment.

Clinical Laboratory Scientists at the Universidade de Sao Paulo (Sao Paulo, Brazil) enrolled 181 patients from the pulmonary hypertension ambulatory group with elevated Ht (>55%) and on warfarin therapy. All patients were diagnosed with polycythemia due to pulmonary hypertension and received anticoagulation treatment at the anticoagulation ambulatory center.

Paired citrate-adjusted and unadjusted blood specimens were tested using the PT test using two different thromboplastin reagents that are routinely used in their laboratory: the first was the HemosIL RecombiPlasTin 2G, with a thromboplastin (International Sensitivity Index [ISI] 1.00) of lyophilized recombinant human tissue factor (RTF), and the second reagent was HemosIL PT-Fibrinogen HS Plus with a thromboplastin (ISI 1.24) lyophilized from rabbit brain extract (HS Plus). Both reagents were produced by Instrumentation Laboratories (Bedford, MA, USA). The results are expressed as the international normalized ratio (INR). The correlation and percent change (% change) between sample pairs were calculated.

The scientists reported that the INR-RTF results from adjusted and unadjusted citrate blood specimens showed a strong correlation. The INR median was 2.25 for citrate-adjusted samples and was 2.22 for citrate-unadjusted samples. For samples with Ht >62%, the % change between sample pairs was >10%. Results using HS Plus showed a moderate correlation between citrate-adjusted and unadjusted samples. The INR median was 2.51 for citrate-adjusted samples and 3.45 for citrate-unadjusted samples. For samples with Ht>55%, the % change between sample pairs was higher than 10%.

The authors concluded that the adjustment of citrate concentration in samples with markedly elevated hematocrit depends on the PT reagent used in the routine tests, and each laboratory must perform a validation assay. Their data suggest that with RecombiPlasTin 2G reagent, samples of patients with polycythemia on warfarin therapy with Ht up to 62% could be obtained in an unadjusted citrate concentration tube. Using this PT reagent, can reduce the number of collection tubes and length of patient stay and avoid recall of patients, meaning lower treatment costs and faster patient care. The study was published in the November. 2020 issue of the journal Practical Laboratory Medicine.

Related Links:
Universidade de Sao Paulo
Instrumentation Laboratories

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Gel Cards
DG Gel Cards
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.